MADJAR

What if an altered perception prevents you from identifying a symptom that indicates a serious disease?

A recent study by researchers at Stanford University School of Medicine, published in Nature Health in January 2026, examined whether a common variation in human perception–color vision deficiency–might influence outcomes in diseases where color is the primary warning sign. Their focus was simple and striking: if you cannot reliably perceive the color red, are you less likely to notice blood in your urine–often the first symptom of bladder cancer? And if so, does that matter?

What we commonly call color blindness isn’t blindness. The more accurate term is color vision deficiency (CVD). Vision is typically sharp, and the world is fully visible in form, motion, and detail. What is altered is the ability to distinguish certain wavelengths of light, most commonly along the red-green axis. Colors appear muted or shifted; reds may look brownish or gray. Many individuals live their entire lives without major difficulty. But when a medical symptom depends on detecting a color change–such as the reddish tint of blood in urine–this subtle difference in perception can become the difference between early and delayed diagnosis, between life and death.

Color vision deficiency shares similarities with other situations in which the sensory system is intact, but a specific channel of interpretation is missing or altered. Consider prosopagnosia, the inability to recognize faces despite normal vision; or amusia, commonly known as tone deafness, in which pitch differences are difficult to discern. In each case, the world is present, but not fully recognized.

Color vision deficiency arises in the retina, within specialized cells called cone photoreceptors. These cells contain light-sensitive proteins known as opsins, each tuned to a different range of wavelengths. Humans normally have three types: S-cones (blue), M-cones (green), and L-cones (red). In red-green color vision deficiency, the genes encoding the red or green opsins are either absent or altered.

This condition is typically inherited in an X-linked recessive pattern. The genes for the red and green opsins are located on the X chromosome. Because men have only one X chromosome, a single altered gene is sufficient to produce the condition. Women, with two X chromosomes, are more often carriers and less frequently affected. As a result, color vision deficiency is far more common in men, affecting up to 8% in some populations.

The researchers compared patients with and without CVD using large-scale electronic health records. They identified 135 patients with bladder cancer and color vision deficiency, each matched to similar patients without the condition, and a separate cohort of 187 patients with colorectal cancer analyzed in the same way. Their most notable finding was a significantly higher long-term mortality from bladder cancer among individuals with color vision deficiency.

Over a 20-year period, patients with bladder cancer and color vision deficiency had a 52% higher risk of death compared with those with normal color vision. Survival curves showed that only about half of these patients were alive ten years after diagnosis, compared with roughly three-quarters of those without the deficiency. Patients with color vision deficiency were also more likely to be diagnosed at a more advanced stage, suggesting delayed recognition of symptoms.

The mechanism is both simple and unsettling. Early bladder cancer often presents with painless hematuria–blood in the urine. For most patients, this is detected visually: the urine appears pink, red, or tea-colored. It is a symptom that should not be ignored. But for someone with red-green color vision deficiency, this change may not register as abnormal. The urine may appear darker, but not distinctly bloody. Diagnosis is delayed. Disease progresses.

Interestingly, the study did not find a similar increase in mortality from colorectal cancer, another disease in which blood may be visible–this time in the stool. The difference likely lies in the redundancy of symptoms and screening pathways. Colorectal cancer often presents with additional signs–changes in bowel habits, abdominal discomfort, weight loss–and is subject to routine screening through colonoscopy or stool-based tests. Detection does not rely solely on visual perception of blood. Bladder cancer, by contrast, may present with hematuria as its only early clue.

The conclusion is not that color vision deficiency is dangerous in itself, but that medicine often assumes a shared perceptual baseline that does not exist. Symptoms are not merely biological events; they are experiences filtered through the senses. When a key dimension of perception is altered, the pathway from disease to diagnosis can be disrupted.

I asked, what if an altered perception prevents you from identifying a symptom that indicates a serious disease? The answer, it seems, is that the disease does not announce itself any less clearly–it is simply written in a language some patients cannot fully read. And the consequences can be profound.